NCI Natural Product Drug Development To Get New Emphasis; Suggestions Of Critic Accepted
In Brief: Grants To Get Biggest Share Of NCI’s Extra $74 Million; A PR Failure In Pittsburgh
FDA’s New Guideline Proposal Meets More NCI Objections
FDA Holds Up Another IND; Rauscher, FDA Commissioner Hold “Excellent” Meeting
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Anthony Letai reflects on Year One as NCI Director: “The NCI is in business”









